68P Patient-reported outcomes (PROs) in Chinese patients with mantle cell lymphoma (MCL) after covalent Bruton’s tyrosine kinase inhibitor (cBTKi) treatment: Post-hoc analysis from a phase II study — Yuqin Song (2024) | RDL Network
68P Patient-reported outcomes (PROs) in Chinese patients with mantle cell lymphoma (MCL) after covalent Bruton’s tyrosine kinase inhibitor (cBTKi) treatment: Post-hoc analysis from a phase II study
Hans Gelderblom, Robin L. Jones, Jean Yves Blay, Suzanne George, Patrick Schöffski, Margaret von Mehren, John Zalcberg, Yoon‐Koo Kang, Albiruni Ryan Abdul Razak, Jonathan C. Trent, Steven Attia, Axel Le Cesne, B. Harrow, Claus Becker, Tao Wang, Matthew L. Sherman, Rodrigo Ruiz‐Soto, Michael C. Heinrich, Sebastian Bauer
Hans Gelderblom, Robin L. Jones, Jean Yves Blay, Suzanne George, Margaret von Mehren, John Zalcberg, Yoon‐Koo Kang, Albiruni Abdul Razak, Jonathan C. Trent, Steven Attia, Axel Le Cesne, Brittany L. Siontis, David Goldstein, Kjetil Boye, César Sánchez, Neeltje Steeghs, Piotr Rutkowski, Mihaela Druta, César Serrano, Neeta Somaiah, Ping Chi, ,
Jean Yves Blay, Hans Gelderblom, P Rutkowski, AJ Wagner, M van de Sande, Silvia Stacchiotti, Axel Le Cesne, E Palmerini, Marc Vallee, B. Harrow, Christoph R. Becker, Rudresh Jarecha, Maitreyi G. Sharma, W.D. Tap
Alessandra Tedeschi, Meletios A Dimopoulos, Judith Trotman, Ramón García‐Sánz, D. Blair Macdonald, Beatrice Mahé, Charles Herbaux, Leonard T. Heffner, Constantine S. Tam, Marzia Varettoni, M. Lia Palomba, J. Matous, Chaim Shustik, Efstathios Kastritis, Steven P. Treon, J. Li, Erik Poulsen, B. Hauns, Christian Buske, V. Leblond
Discussion(0)
No comments yet. Be the first to comment.